SRTA

Strata Critical Medical, Inc.

Strata Critical Medical, Inc. (SRTA) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Value (C-). The rating has held at C for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C-
Factor Score 1.9 / 5.0
Growth
B-
Factor Score 2.9 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
C
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA 51.7
Rev Growth YoY 50.3%
Gross Margin 21.6%
Price Return 3M -6.6%
Price Return 12M 8.0%
Catalyst Signal 0.00
Market Cap $492.2M
TTM Revenue $280.8M
Price / Sales 1.8
ROE -7.6%

Historical Factor Score Progression

Held C for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C- (1.9) B- (2.9) C- (2.1) C (2.5) C+ (2.6) C (2.4)
2026-11-08 D+ (1.7) B- (2.9) C- (2.1) C (2.4) C+ (2.6) C (2.4)
2026-11-01 C- (1.9) B- (3.1) C (2.2) C (2.4) C+ (2.7) C (2.4)
2026-10-25 C- (1.9) B- (3.1) C (2.2) C+ (2.7) C+ (2.6) C (2.5)
2026-10-18 C- (1.9) B- (3.1) C (2.2) C+ (2.8) C+ (2.6) C+ (2.5)
Page 1 of 4